Botox Cosmetic Injection, Powder, Lyophilized, For Solution
Product Images NDC 0023-9232

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Botox Cosmetic (NDC 0023-9232). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: (Botox 01)

An instructional diagram showing a front view of a human face with marked injection sites indicated by 'x' symbols on the forehead and between the eyebrows, likely illustrating typical areas for intramuscular administration.*

FDA Label Image

Figure 2 And 3 (Botox 02)

Illustration diagram showing injection site angles and distances related to the eye area, likely demonstrating intramuscular injection technique for BOTOX Cosmetic. The diagrams indicate measurements in centimeters and angles of 30 degrees relative to anatomical landmarks near the outer corner of the eye.*

FDA Label Image

Figure 4: (Botox 03)

An illustration showing the injection sites for BOTOX Cosmetic on the forehead. The diagram marks the midline, superior margin of frontalis activity, upper and lower treatment rows, and eyebrow positions, indicating specific points for intramuscular injection.*

FDA Label Image

Figure 5: Injection Sites For Platysma Prominence (2 Bands) (Botox 04)

A line graph comparing the percentage of subjects scoring none or mild over study days between BOTOX Cosmetic 240 units and placebo groups. The x-axis represents study days, and the y-axis shows the percentage of subjects. The BOTOX Cosmetic group shows a peak early in the study period, followed by a gradual decline, while the placebo group remains consistently low throughout.*

FDA Label Image

Figure 6: Injection Sites For Platysma Prominence (1 Band) (Botox 05)

A line graph depicting the percentage of subjects scoring none or mild over a study period of 180 days. The graph compares BOTOX Cosmetic 20U FHL with 20U GL and a placebo group. The x-axis represents study days within treatment cycle 1, and the y-axis shows the percentage of subjects scoring none or mild.*

FDA Label Image

Figure 7 (Botox 06)

A line graph depicting the percentage of subjects scoring None or Mild over 180 days following treatment cycles. The x-axis represents study days from 1 to 180, and the y-axis shows the percentage of subjects from 0 to 100%. The graph compares responses for BOTOX Cosmetic under different treatment regimens versus placebo.*

FDA Label Image

Figure 8: Percentage Of Subjects With Treatment Success (achieving None Or Mild Fhl From Baseline At Maximum Eyebrow Elevation) By Visit (study 1) (Botox 07)

A line graph showing the percentage of subjects scoring none or mild over study days within treatment cycle 1 up to day 180. It compares BOTOX Cosmetic 20U FHL with 20U GL versus placebo. The y-axis represents the percentage of subjects, and the x-axis represents study days (1, 7, 14, 30, 60, 90, 120, 150, 180). The BOTOX Cosmetic group shows a higher percentage of subjects scoring none or mild compared to placebo across all time points.*

FDA Label Image

Figure 9: Percentage Of Subjects With Treatment Success (achieving None Or Mild Fhl From Baseline At Maximum Eyebrow Elevation) By Visit (study 2) (Botox 08)

FDA Label Image

Figure 10 (Botox 09)

The image shows the packaging label for BOTOX Cosmetic injection, lyophilized powder for solution, containing 50 Units per vial of onabotulinumtoxinA. The label features the product name, concentration, and manufacturer Allergan, Inc. The packaging includes storage instructions and a barcode. The design uses mainly purple and white tones with the Allergan logo.*

FDA Label Image

Figure 11 (Botox 0a)

Packaging label for BOTOX Cosmetic 100 units/vial injection, lyophilized powder for intramuscular use. The label includes the proprietary name, generic name onabotulinumtoxinA, strength, Allergan, Inc. as labeler, and storage instructions. The design features a purple gradient background and includes a barcode and NDC number.*

FDA Label Image

Logodescription Automatically Generated (Botox 0b)

FDA Label Image

A Black And White Logodescription Automatically Generated (Botox 0c)

FDA Label Image

Principal Display Panelndc 0023-3919-50botox®cosmeticonabotulinumtoxinafor Injection50units/vialallergan Aestheticsan Abbvie Company (Botox 0d)

Packaging label for BOTOX Cosmetic 50 Units/vial injection powder (lyophilized) for intramuscular use by Allergan, Inc. The carton indicates storage instructions, vial content of 50 Units of onabotulinumtoxinA, and directs to dispense the Medication Guide. It notes single-dose vial, reconstitution guidelines, and a barcode on the side panel.*

FDA Label Image

Principal Display Panelndc 0023-9232-01botox®cosmeticonabotulinumtoxinafor Injection100units/vialallerganaesthetics An Abbvie Company (Botox 0e)

The packaging label shows BOTOX Cosmetic injection by Allergan Aesthetics, containing onabotulinumtoxinA. It indicates a dosage strength of 100 Units per vial in a powder form for intramuscular injection. The label includes storage instructions, that the vial is single-dose, and directions to reconstitute with nonpreserved saline. Manufacturer details and barcode are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.